Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Possis shareholder lawsuit dismissed

This article was originally published in The Gray Sheet

Executive Summary

U.S. Court of Appeals for the Eighth Circuit on March 24 affirms a previous decision by the U.S. District Court for the District of Minnesota to dismiss with prejudice a shareholder lawsuit filed June 5, 2005 against Minneapolis endovascular device firm Possis Medical and two of its executive officers. The suit had alleged the firm misrepresented material information about the company's AngioJet Rheolytic thrombectomy system prior to its August 2004 disclosure of results from its AiMI clinical trial, Possis said. Bayer HealthCare acquired Possis for $361 million in February (1"The Gray Sheet" Feb. 18, 2008, p. 10)

You may also be interested in...



Bayer Builds Cardiovascular Franchise With Possis Purchase

Bayer HealthCare will expand its cardiovascular device offerings by acquiring AngioJet thrombectomy system maker Possis Medical for $361 million under a deal announced Feb. 11

Novartis In Line For Ofatumumab MS Approval In June

Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.

ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

UsernamePublicRestriction

Register

MT025951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel